TGen identifies gene that could help prevent or delay onset of Alzheimer’s disease

Boosting ABCC1 could lessen the production of plaque linked to Alzheimer’s development

PHOENIX, Ariz. — April 13, 2021 — Findings of a study by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that increasing expression of a gene known as ABCC1 could not only reduce the deposition of a hard plaque in the brain that leads to Alzheimer’s disease, but might also prevent or delay this memory-robbing disease from developing.

Continue reading

ASU is among the leaders in patents granted, start-ups launched

Tempe, Ariz., April 8, 2021 Arizona State University, through Skysong Innovations, continues to achieve high rankings in technology transfer metrics. The latest read on this is a survey by the Association of University Technology Managers (AUTM). According to AUTM’s most recent survey (fiscal year 2019), ASU was fourth in patents granted, fourth in startups companies launched and third in inventions disclosed when compared to other universities without a medical school.

Continue reading

Life365 Continues to Build Upon Its Hospital@Home Product Offering with Eat Fit Go Partnership

SCOTTSDALE, AZ, April 6, 2021— Life365, a leading virtual care platform provider, announced its partnership with EAT FIT GO Wellness, a healthy lifestyles company that empowers wellbeing from the inside out with premium, convenient and healthy nutrition. EAT FIT GO specializes in ready to heat and serve healthy prepackaged meals designed to be affordable, convenient and nutritious.

Continue reading

NIH clinical trial evaluating Moderna COVID-19 variant vaccine begins

Early-stage trial to evaluate safety and immunogenicity.

In investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial evaluating the vaccine candidate’s safety and immunogenicity in adult volunteers. The vaccine, known as mRNA-1273.351, was developed by the biotechnology company ModernaTX, Inc., based in Cambridge, Massachusetts. The trial is led and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial will enroll approximately 210 healthy adult volunteers at four clinical research sites in the United States that are part of the NIAID-funded Infectious Diseases Clinical Research Consortium(IDCRC).

Continue reading

BD Announces FDA Emergency Use Authorization for Combination COVID-19, Flu Rapid Antigen Test

New Test on the BD Veritor™ Plus System Can Detect SARS-CoV-2, Influenza A, Influenza B from Single Patient Sample

FRANKLIN LAKES, N.J., March 30, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for a new, rapid antigen test that can detect SARS-CoV-2, influenza A and influenza B in a single test.

Continue reading

Mayo Clinic and ASU MedTech Accelerator boosts health startups

The partnership propels a new cohort of next-generation medical technology and service startups forward with one-of-a-kind tools and resources.

Few things have better illustrated the need for innovative medical technologies than the COVID-19 pandemic. The Mayo Clinic and ASU MedTech Accelerator, a flagship program of the Mayo Clinic and ASU Alliance for Health Care, was designed to help empower medical startups to better navigate challenges while bringing forth life-changing health innovations. The second cohort of this program is set to launch March 30, 2021.

Continue reading

Life365 Adds AliveCor’s Personal EKG Technology to their Virtual Care Platform

SCOTTSDALE, AZ, March 30, 2021— Life365, a leading virtual care platform provider, announced its integration of products from AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, to enhance their remote cardiac monitoring solutions for healthcare consumers and patients located outside traditional care settings.

Continue reading

Equine Amnio Solutions Signs Exclusive Agreement For Distribution Of RenoVō®, A Next-Generation Equine Regenerative Product

ARGYLE, Texas, March 25, 2021 /PRNewswire/ — Equine Amnio Solutions, LLC (EAS), a distributor of advanced, next-generation equine regenerative products, announced today that Covetrus, a global leader in animal-health technology and services, will be the exclusive distributor of the RenoVō® equine allograft throughout the United States.

Continue reading